Pralatrexate (Fotolyn) beats tarceva on survival as 2nd line Rx for advanced non-small cell #lungcancer in smokers: http://bit.ly/aVC97L

Related posts:

Amgen’s denosumab beats FDA-ap… Amgen’s denosumab beats FDA-approved Zometa in preventing skeletal-relate...

Trial of novel chemo agent pra… Trial of novel chemo agent pralatrexate vs. tarceva in current/former smokers completed...

About to give good news to lon… About to give good news to longtime smoking pt w/met NSCLC that her tumor’...

Important #lungcancer trial te… Important #lungcancer trial tests chemo/Tarceva vs. Tarceva alone in never- or ligh...

Unfortunately, picoplatin fail… Unfortunately, picoplatin fails to improve survival compared to supportive care i...